Complete Blood Count (CBC) devices are used to analyze the components present in the blood such as white blood cells, red blood cells, platelets, hemoglobin and hematocrit levels. CBC testing provides important information about overall health and detects conditions such as anemia, infection and leukemia. Advancements in technologies have led to development of Point-Of-Care (POC) CBC devices which are portable, easy-to-use and provide quick results. The increasing demand for such user-friendly and compact devices is fueling the market growth. The Global Complete Blood Count Device Market is estimated to be valued at US$ 4922.18 Mn in 2024 and is expected to exhibit a CAGR of 12.% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the Complete Blood Count Device are Agilent Technologies, Inc., BD, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Danaher, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Merck KGaA, Shimadzu Corporation, Hitachi, Ltd., Bruker, Oxford Instruments, ZEISS International, Genome Medical, Inc., Hamilton Company, and Beckman Coulter, Inc. These players are focusing on new product launches and geographic expansions to gain competitive edge.

The rising prevalence of chronic diseases worldwide along with growing elderly population who are more prone to such conditions is creating strong demand for CBC diagnostic testing. This offers key opportunities for market players to introduce affordable and user-friendly POC devices especially in developing regions.

Geographic expansion into emerging Asian countries presents excellent scope for complete blood count device manufacturers. Factors such as improving healthcare infrastructure, growing health awareness and rising disposable incomes in countries like India and China will drive the demand in these markets over the forecast period.

Market drivers: Rapidly growing geriatric population globally who are at high-risk of developing blood-related conditions is a major market driver. Increased investments by governments and private organizations in digital POC diagnostics will also propel the market growth.

Market restraints: High costs associated with automated complete blood count devices limits their applications especially in price-sensitive developing markets. Stringent regulatory approvals for new product launches is another challenge for market players.
Segment Analysis

The Complete Blood Count Device Market Demand  is segmented into hematology analyzers, flow cytometers and hemostasis analyzers. Hematology analyzers held the largest market share (~30%) due to increasing adoption of automated hematology analyzers for routine hematology testing. These analyzers reduce turnaround time and provide accurate and reliable results. Flow cytometers are gaining prominence for applications in immunology testing and cancer research. Advancements in flow cytometry techniques have increased sensitivity and enabled high throughput screening of multiple cell parameters simultaneously.

Regional Analysis
North America dominated the global complete blood count device market in 2024 with a share of over 35% owing to the region's well-established healthcare infrastructure and availability of advanced diagnostic technologies. Asia Pacific is poised to witness the fastest growth during the forecast period due to rising healthcare expenditure, large patient population and increasing government focus on early disease diagnosis and prevention in countries such as India and China. Additionally, expanding private sector and growing penetration of healthcare insurance are some factors fueling the regional market.

For more insights, read-https://www.newsstatix.com/complete-blood-count-device-market/

Check more trending articles related to this topic:https://techaxen.com/glycerol-the-versatile-elixir-fueling-industries-and-nurturing-skincare-unveiling-the-liquid-golds-hidden-potentials/